{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:50:21Z","timestamp":1781585421581,"version":"3.54.5"},"reference-count":33,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The treatment of chronic lymphocytic leukemia (CLL) currently relies on the use of chemo-immunotherapy, Bruton\u2019s tyrosine kinase inhibitors, or BCL2 inhibitors alone or combined with an anti-CD20 monoclonal antibody. However, the availability of multiple choices for the first-line setting and a lack of direct head-to-head comparisons pose a challenge for treatment selection. To overcome these limitations, we performed a systematic review and a network meta-analysis on published randomized clinical trials performed in the first-line treatment setting of CLL. For each study, we retrieved data on progression-free survival (according to del17\/P53 and IGHV status), overall response rate, complete response, and incidence of most frequent grade 3\u20134 adverse event. We identified nine clinical trials encompassing 11 different treatments, with a total of 5288 CLL patients evaluated. We systematically performed separated network meta-analyses (NMA) to evaluate the efficacy\/safety of each regimen in the conditions previously described to obtain the surface under the cumulative ranking curve (SUCRA) score, which was subsequently used to build separated ranking charts. Interestingly, the combination of obinutuzumab with acalabrutinib reached the top of the chart in each sub-analysis performed, with the exception of the del17\/P53mut setting, where it was almost on par with the aCD20 mAbs\/ibrutinib combination (SUCRA aCD20-ibrutinib and O-acala: 93.5% and 91%, respectively) and of the safety evaluation, where monotherapies (acalabrutinib in particular) gave better results. Finally, considering that NMA and SUCRA work for single endpoints only, we performed a principal component analysis to recapitulate in a cartesian plane the SUCRA profiles of each schedule according to the results obtained in each sub-analysis, confirming again the superiority of aCD20\/BTKi or BCL2i combinations in a first-line setting. Overall, here we demonstrated that: (1) a chemotherapy-free regimen, such as the combination of aCD20 with a BTKi or BCL2i, should be the preferred treatment choice despite biological\/molecular characteristics (preferred regimen O-acala); (2) there is less and less room for chemotherapy in the first line treatment of CLL.<\/jats:p>","DOI":"10.3390\/ijms24129930","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T02:59:57Z","timestamp":1686279597000},"page":"9930","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials"],"prefix":"10.3390","volume":"24","author":[{"given":"Andrea","family":"Rizzuto","sequence":"first","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, 90141 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Pirrera","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, 90141 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Gigliotta","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, 90141 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatrice","family":"Mancuso","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, 90141 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candida","family":"Vullo","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, 90141 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Maria","family":"Camarda","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, 90141 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Rotolo","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, 90141 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Roppolo","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, 90141 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Spoto","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, 90141 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5256-0726","authenticated-orcid":false,"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[{"name":"Hematology Unit, \u201cAnnunziata\u201d Hospital of Cosenza, 87100 Cosenza, Italy"},{"name":"Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1522-4504","authenticated-orcid":false,"given":"Cirino","family":"Botta","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, 90141 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Siragusa","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, 90141 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"ref_1","first-page":"S41","article-title":"Chronic lymphocytic leukemia","volume":"38","author":"Dighiero","year":"1996","journal-title":"Hematol. Cell Ther."},{"key":"ref_2","unstructured":"(2022, July 07). Chronic Lymphocytic Leukemia\u2014Cancer Stat Facts, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Stilgenbauer","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1007\/s00277-018-3503-6","article-title":"Prognostic and therapeutic stratification in CLL: Focus on 17p deletion and p53 mutation","volume":"97","author":"Buccheri","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","article-title":"VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia","volume":"100","author":"Seiler","year":"2002","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood-2015-10-620864","article-title":"Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis","volume":"127","author":"Parikh","year":"2016","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: Results from a multicenter study of 683 patients","volume":"28","author":"Mato","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): A randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet Lond. Engl."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): Follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Zhang","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/leu.2015.14","article-title":"Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: Updated results of the CLL11 study","volume":"29","author":"Goede","year":"2015","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): A multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet Lond. Engl."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.clml.2020.10.012","article-title":"Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis","volume":"21","author":"Molica","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e820","DOI":"10.1016\/j.clml.2021.06.010","article-title":"Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves","volume":"21","author":"Alrawashdh","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/cncr.26360","article-title":"Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737","volume":"118","author":"Kojima","year":"2012","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib\u2013rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/bloodadvances.2016003905","article-title":"Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in relapsed\/refractory patients","volume":"1","author":"Botta","year":"2017","journal-title":"Blood Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"643490","DOI":"10.3389\/fonc.2021.643490","article-title":"Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens","volume":"11","author":"Botta","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hon.3041","article-title":"Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant","volume":"40","author":"Botta","year":"2022","journal-title":"Hematol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Chaimani, A., Higgins, J.P.T., Mavridis, D., Spyridonos, P., and Salanti, G. (2013). Graphical tools for network meta-analysis in STATA. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0076654"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Salanti, G., Del Giovane, C., Chaimani, A., Caldwell, D.M., and Higgins, J.P.T. (2014). Evaluating the quality of evidence from a network meta-analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0099682"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/j.1541-0420.2010.01389.x","article-title":"Robust clustering using exponential power mixtures","volume":"66","author":"Zhang","year":"2010","journal-title":"Biometrics"},{"key":"ref_33","unstructured":"Maechler, M., Rousseeuw, P., Struyf, A., Hubert, M., and Hornik, K. (2023, February 22). cluster: Cluster Analysis Basics and Extensions. R Package Version 2.1.4. Available online: https:\/\/CRAN.R-project.org\/package=cluster."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/12\/9930\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:51:20Z","timestamp":1760125880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/12\/9930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":33,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["ijms24129930"],"URL":"https:\/\/doi.org\/10.3390\/ijms24129930","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,9]]}}}